Clinical observation of sacubitril/valsartan versus benazepril in perimenopausal hypertensive patients

ZHANG Xiaoxia; SHAO Bolin; ZHOU Yingkun; ZHANG Zhanhai; LI Zhiying

doi:10.6039/j.issn.1001-0408.2026.04.11

您当前的位置：

首页 >

文章列表页 >

Clinical observation of sacubitril/valsartan versus benazepril in perimenopausal hypertensive patients

更新时间：2026-02-27

- Clinical observation of sacubitril/valsartan versus benazepril in perimenopausal hypertensive patients
- ZHONGGUO YAOFANG Vol. 37, Issue 4, Pages: 476-479(2026)
- 作者机构：
  
  南阳医学高等专科学校第一附属医院心血管内科，河南南阳　473058
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2026.04.11
  CLC： R969.4;R714.25
- Received：13 October 2025，
  
  Revised：2026-02-03，
  
  Accepted：03 February 2026，
  
  Published：28 February 2026
- 稿件说明：
移动端阅览
张晓霞,邵柏林,周英坤,等.沙库巴曲缬沙坦对比贝那普利用于围绝经期高血压患者的临床观察[J].中国药房,2026,37(04):476-479.

ZHANG Xiaoxia,SHAO Bolin,ZHOU Yingkun,et al.Clinical observation of sacubitril/valsartan versus benazepril in perimenopausal hypertensive patients[J].ZHONGGUO YAOFANG,2026,37(04):476-479.
张晓霞,邵柏林,周英坤,等.沙库巴曲缬沙坦对比贝那普利用于围绝经期高血压患者的临床观察[J].中国药房,2026,37(04):476-479. DOI： 10.6039/j.issn.1001-0408.2026.04.11.

ZHANG Xiaoxia,SHAO Bolin,ZHOU Yingkun,et al.Clinical observation of sacubitril/valsartan versus benazepril in perimenopausal hypertensive patients[J].ZHONGGUO YAOFANG,2026,37(04):476-479. DOI： 10.6039/j.issn.1001-0408.2026.04.11.

摘要

目的

比较沙库巴曲缬沙坦与贝那普利用于围绝经期高血压患者的降压效果及对心室重构、炎症纤维化的影响。

方法

回顾性收集我院2023年1月1日至2024年12月30日收治的206例围绝经期高血压患者资料，按用药的不同分为贝那普利组（105例）和沙库巴曲缬沙坦组（101例）。贝那普利组患者给予盐酸贝那普利片，沙库巴曲缬沙坦组患者给予沙库巴曲缬沙坦钠片，所有患者均治疗6个月。观察并比较两组患者治疗前后的血压（收缩压、舒张压）及血压达标情况、心脏超声指标（左室射血分数、左室质量指数、相对壁厚、二尖瓣口舒张早期峰值血流速度/二尖瓣环舒张早期峰值运动速度）、炎症纤维化相关指标（超敏C反应蛋白、单核细胞与淋巴细胞比值、中性粒细胞与淋巴细胞比值）及不良反应（低血压、高钾血症、血管性水肿）发生情况。

结果

沙库巴曲缬沙坦组患者的血压达标率显著高于贝那普利组（

＜0.05）。治疗后，两组患者的血压、心脏超声指标（左室射血分数除外）、炎症纤维化相关指标水平均显著低于同组治疗前，且沙库巴曲缬沙坦组显著低于同期贝那普利组（

＜0.05）。两组患者低血压、高钾血症、血管性水肿的发生率及不良反应总发生率比较，差异均无统计学意义（

＞0.05）。

结论

与贝那普利比较，沙库巴曲缬沙坦能更有效地控制围绝经期高血压患者的血压，逆转心室重构及抑制炎症纤维化，且二者的安全性相当。

Abstract

OBJECTIVE

To compare the antihypertensive efficacy of sacubitril/valsartan versus benazepril in patients with perimenopausal hypertension， as well as their impacts on ventricular remodeling and inflammatory fibrosis.

METHODS

A total of 206 perimenopausal hypertensive patients in our hospital from January 1， 2023 to December 30， 2024 were retrospectively included.These patients were enrolled and divided into benazepril group （105 cases） and sacubitril/valsartan group （101 cases）. Benazepril group received Benazepril hydrochloride tablet， and sacubitril/valsartan group received Sacubitril valsartan sodium tablet. All patients were treated for 6 months. The blood pressure（systolic blood pressure and diastolic blood pressure） and blood pressure control status before and after treatment， echocardiographic indicators （left ventricular ejection fraction， left ventricular mass index， relative wall thickness， and early-diastolic peak transmitral flow velocity/early-diastolic peak velocity of the mitral annulus）， inflammatory fibrosis related indicators（high-sensitivity C-reactive protein，ratio of monocytes to lymphocytes，and ratio of neutrophils to lymphocytes）， as well as the occurrence of adverse reactions（hypotension，hyperkalemia，and angioedema） were observed in both groups before and after treatment.

RESULTS

The blood pressure control rate was significantly higher in the sacubitril/valsartan group than in benazepril group （

＜0.05）. After treatment， the blood pressure， echocardiographic indicators（except for left ventricular ejection fraction），and inflammatory fibrosis related indicators were significantly lower than those before treatment within the same group， and the sacubitril/valsartan group were significantly lower than the benazepril group （

＜0.05）. There were no statistically significant differences in the incidence of hypotension， hyperkalemia， angioedema， and overall adverse drug reactions between the two groups （

＞0.05）.

CONCLUSIONS

Compared with benazepril， sacubitril/valsartan provides superior blood-pressure control， reverses ventricular remodeling， attenuates inflammatory fibrosis in perimenopausal hypertensive patients， while maintaining a similar safety profile.

关键词

Keywords

references

DURALDE E R ， SOBEL T H ， MANSON J E . Management of perimenopausal and menopausal symptoms [J ] . BMJ ， 2023 ， 382 ： e072612 .

LI Z ， GUO J P ， HUANG L . Perimenopausal syndrome and hypertension during perimenopause in South China：prevalence，relationships and risk factors [J ] . BMC Womens Health ， 2024 ， 24 （ 1 ）： 215 .

张寅梅，王文婷，朱露露，等 . 围绝经期女性自主神经对血压的影响及相关机制的研究进展 [J ] . 中华高血压杂志， 2024 ， 32 （ 5 ）： 424 - 431 .

张帅，俞峰，郑毅敏，等 . 围绝经期高血压患者心血管结构功能特点及相关影响因素分析 [J ] . 中国妇幼保健， 2023 ， 38 （ 17 ）： 3358 - 3361 .

中国高血压防治指南修订委员会，高血压联盟（中国，中国医疗保健国际交流促进会高血压分会，等 . 中国高血压防治指南：2024年修订版 [J ] . 中华高血压杂志， 2024 ， 32 （ 7 ）： 603 - 700 .

SOTILLO S ， WARD J L ， GUILLOT E ， et al . Dose-response of benazepril on biomarkers of the classical and alternative pathways of the renin-angiotensin-aldosterone system in dogs [J ] . Sci Rep ， 2023 ， 13 （ 1 ）： 2684 .

许顶立，宋霖 . 《中国心力衰竭诊断和治疗指南2024》解读 [J ] . 临床心血管病杂志， 2024 ， 40 （ 6 ）： 437 - 439 .

LAUDER L ， MAHFOUD F ， BÖHM M . Management of resistant hypertension [J ] . Annu Rev Med ， 2024 ， 75 ： 443 - 457 .

JANGID M K ， DOSHI G M . Cross talk on therapeutic strategies：natriuretic peptides and inhibiting neprilysin in hypertension management [J ] . Hypertens Res ， 2025 ， 48 （ 1 ）： 284 - 300 .

RYCZKOWSKA K ， ADACH W ， JANIKOWSKI K ， et al . Menopause and women’s cardiovascular health：is it really an obvious relationship? [J ] . Arch Med Sci ， 2023 ， 19 （ 2 ）： 458 - 466 .

LIU J J ， JIN X S ， LIU W B ， et al . The risk of long-term cardiometabolic disease in women with premature or early menopause：a systematic review and meta-analysis [J ] . Front Cardiovasc Med ， 2023 ， 10 ： 1131251 .

MCMURRAY J ， JACKSON A ， LAM C ， et al . Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction：insights from PARAGON-HF [J ] . Circulation ， 2020 ， 141 （ 5 ）： 338 - 351 .

ZHANG Y L ， ZHAO X Y ， HUANG H ， et al . Network meta-analysis of sacubitril/valsartan for the treatment of essential hypertension [J ] . Clin Res Cardiol ， 2023 ， 112 （ 7 ）： 855 - 867 .

WU S P ， FENG X X ， ZHENG H ， et al . Sex-specific associa-tion of left ventricular hypertrophy with cardiovascular events in high-risk of cardiovascular disease population：findings from the sub-cohort of China PEACE million persons project [J ] . J Clin Hypertens ， 2025 ， 27 （ 5 ）： e70072 .

MUSTAFA N H ， JALIL J ， ZAINALABIDIN S ， et al . Molecular mechanisms of sacubitril/valsartan in cardiac remodeling [J ] . Front Pharmacol ， 2022 ， 13 ： 892460 .

CHEN J S ， PEI Y ， WANG Q Y ， et al . Effect of sacubitril/valsartan or valsartan on ventricular remodeling and myocardial fibrosis in perimenopausal women with hypertension [J ] . J Hypertens ， 2023 ， 41 （ 7 ）： 1077 - 1083 .

YANG P ， LI X K ， WANG L J ， et al . Effects of sacubitril/valsartan on cardiac reverse remodeling and cardiac resynchronization in patients with acute myocardial infarction [J ] . Front Cardiovasc Med ， 2023 ， 9 ： 1059420 .

AHMED S A ， ZHANG B H ， ABDEL-RAHMAN A A . Estrogen-mediated mitigation of cardiac oxidative stress in ovariectomized rats is associated with upregulated cardiac circadian clock Per2 and heart-specific miRNAs [J ] . Life Sci ， 2023 ， 331 ： 122038 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

3种血管紧张素转换酶抑制药对急性心肌梗死患者心室重构的改善作用

Improvement effects and mechanism of Achyranthes bidentata total saponins extract on vascular endothelial dysfunction in spontaneously hypertensive rats

替米沙坦联合贝那普利对永久性心脏起搏器植入患者血浆脑利

外周神经阻滞与腰-硬联合麻醉对老年高血压患者下肢手术应激反应的影响

硝苯地平联合氯沙坦对高血压合并冠心病患者血压和肾功能的影响

Related Author

ZHANG Zufeng

WANG Xiaohong

HAO Xiaohui

WANG Caige

ZHU Qiuping

ZHANG Chao

ZHANG Yuzhi

ZHAO Mingzhong

Related Institution

Central Laboratory， Henan Integrative Medicine Hospital/Henan Academy of Traditional Chinese Medicine

School of Pharmacy， Henan University of Chinese Medicine

Department of Endocrinology,The First Affiliated Hospital of Chongqing Medical University

⁰